Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Alector’s Strategic Pipeline and Promising PGRN Program Justify Buy Rating Despite AL002 Setback
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
STAT2d
Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news
I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Business Insider2d
Alector’s Strategic Innovations and Potential in Neurological Treatments Justify Buy Rating
BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Don't Miss our Black Friday Offers: Unlock your investing potential ...
BTIG Research Cuts Alector (NASDAQ:ALEC) Price Target to $5.00
Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...
bovnews2d
Alector Inc (ALEC) Posted -257.54% Profit Margin Last Year—Can It Hold Up?
On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $3.96 which represents a slight increase of $0.02 or 0.51% from the prior close of $3.94. The stock opened at $4.01 and ...